Laurel Wealth Advisors Inc. Has $1.56 Million Position in SPDR S&P Biotech (NYSEARCA:XBI)

Laurel Wealth Advisors Inc. trimmed its position in SPDR S&P Biotech (NYSEARCA:XBI) by 18.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,387 shares of the exchange traded fund’s stock after selling 4,160 shares during the quarter. Laurel Wealth Advisors Inc.’s holdings in SPDR S&P Biotech were worth $1,560,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in shares of SPDR S&P Biotech in the 4th quarter valued at approximately $102,000. Captrust Financial Advisors increased its holdings in shares of SPDR S&P Biotech by 126.2% in the 3rd quarter. Captrust Financial Advisors now owns 1,192 shares of the exchange traded fund’s stock valued at $103,000 after acquiring an additional 665 shares during the last quarter. SeaCrest Wealth Management LLC bought a new stake in shares of SPDR S&P Biotech in the 4th quarter valued at approximately $146,000. Calton & Associates Inc. bought a new stake in shares of SPDR S&P Biotech in the 4th quarter valued at approximately $158,000. Finally, First Allied Advisory Services Inc. bought a new stake in shares of SPDR S&P Biotech in the 4th quarter valued at approximately $195,000.

Shares of NYSEARCA XBI opened at $82.90 on Friday. SPDR S&P Biotech has a twelve month low of $66.27 and a twelve month high of $97.98.

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 21st. Stockholders of record on Monday, March 19th were issued a $0.0591 dividend. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.29%. This is an increase from SPDR S&P Biotech’s previous quarterly dividend of $0.03. The ex-dividend date of this dividend was Friday, March 16th.

ILLEGAL ACTIVITY NOTICE: “Laurel Wealth Advisors Inc. Has $1.56 Million Position in SPDR S&P Biotech (NYSEARCA:XBI)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/spdr-sp-biotech-xbi-holdings-reduced-by-laurel-wealth-advisors-inc.html.

SPDR S&P Biotech Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply